• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心脏瓣膜置换术:35年结果的统计回顾

Heart valve replacement: a statistical review of 35 years' results.

作者信息

Grunkemeier G L, Li H H, Starr A

机构信息

Providence Health System, Portland, Oregon, USA.

出版信息

J Heart Valve Dis. 1999 Sep;8(5):466-70; discussion 470-1.

PMID:10517384
Abstract

BACKGROUND AND AIMS OF THE STUDY

Having performed our first heart valve replacement in 1960, we began a prospective lifetime follow up service for all patients, contacting them at least annually to determine survivorship and heart valve complications.

METHODS

We reviewed isolated aortic (AVR) and mitral (MVR) valve replacements from 1960 to 1993, with follow up to 1998. In total, 2,942 AVR and 1,579 MVR were performed, with 21,742 and 12,142 patient-years of follow up, respectively. Analysis of the results affords an opportunity to demonstrate the usefulness and necessity of certain statistical methods, including multivariable event-free analyses and cumulative incidence functions.

RESULTS

The survival rate was 8% at 30 years for both valve positions. However, an overall survival curve is an artificial composite of patients of increasingly higher risk being served during increasingly safer years of calendar time. One result is that, for AVR, age is not a significant univariate risk factor for operative mortality, but is highly significant after accounting for date of surgery using logistic regression. Long-term mortality is higher for tissue valves than for mechanical valves; but mean age is greater (74 versus 57 years), and after accounting for age using Cox regression, mortality is similar for both valve types. Kaplan-Meier analysis estimates thromboembolism occurrences of 85% for AVR and 95% for MVR at 35 and 34 years, respectively, but the cumulative incidence estimates are only 32% and 41%, respectively.

CONCLUSIONS

Prospective follow up for over 35 years has provided an opportunity to illustrate important statistical issues: Multivariate analyses are essential to avoid being misled by excluding important risk factors or including artifactual ones, and the cumulative incidence estimates the percentage of patients who will actually experience a complication.

摘要

研究背景与目的

自1960年完成首例心脏瓣膜置换手术以来,我们开始对所有患者进行前瞻性终身随访服务,至少每年与他们联系一次,以确定生存率和心脏瓣膜并发症情况。

方法

我们回顾了1960年至1993年期间单纯主动脉瓣置换术(AVR)和二尖瓣置换术(MVR),随访至1998年。共进行了2942例AVR和1579例MVR,分别有21742和12142患者年的随访时间。对结果的分析提供了一个机会来证明某些统计方法的实用性和必要性,包括多变量无事件分析和累积发病率函数。

结果

两个瓣膜位置在30年时的生存率均为8%。然而,总体生存曲线是在日历时间越来越安全的年份中,为风险越来越高的患者构建的人为综合曲线。结果之一是,对于AVR,年龄不是手术死亡率的显著单变量风险因素,但在使用逻辑回归考虑手术日期后,年龄具有高度显著性。组织瓣膜术后的长期死亡率高于机械瓣膜;但组织瓣膜患者的平均年龄更大(74岁对57岁),在使用Cox回归考虑年龄因素后,两种瓣膜类型的死亡率相似。Kaplan-Meier分析估计,AVR和MVR在35年和34年时血栓栓塞发生率分别为85%和95%,但累积发病率估计分别仅为32%和41%。

结论

超过35年的前瞻性随访提供了一个机会来说明重要的统计问题:多变量分析对于避免因排除重要风险因素或纳入人为因素而产生误导至关重要,累积发病率可估计实际发生并发症的患者百分比。

相似文献

1
Heart valve replacement: a statistical review of 35 years' results.心脏瓣膜置换术:35年结果的统计回顾
J Heart Valve Dis. 1999 Sep;8(5):466-70; discussion 470-1.
2
Long-term experience with the omniscience cardiac valve.全知型心脏瓣膜的长期经验
J Heart Valve Dis. 1998 Sep;7(5):540-7.
3
Mechanical versus bioprosthetic valve replacement in middle-aged patients.中年患者机械瓣膜置换与生物瓣膜置换的比较
Eur J Cardiothorac Surg. 2006 Sep;30(3):485-91. doi: 10.1016/j.ejcts.2006.06.013. Epub 2006 Jul 20.
4
Clinical evaluation of the carbomedics prosthesis: experience at providence health system in Portland.卡波美迪克斯人工关节的临床评估:波特兰普罗维登斯健康系统的经验
J Heart Valve Dis. 2002 Nov;11(6):844-50.
5
Seventeen-year experience with the St. Jude medical biocor porcine bioprosthesis.使用圣犹达医疗生物猪生物假体的17年经验。
J Heart Valve Dis. 2005 Jul;14(4):486-92.
6
Single-center experience with the On-X prosthetic heart valve between 1996 and 2005.1996年至2005年间使用On-X人工心脏瓣膜的单中心经验。
J Heart Valve Dis. 2007 Sep;16(5):551-7.
7
Five-year follow up of the ATS mechanical heart valve.美国胸科学会(ATS)机械心脏瓣膜的五年随访
J Heart Valve Dis. 2004 Mar;13(2):231-8.
8
North American multicenter experience with the On-X prosthetic heart valve.北美使用On-X人工心脏瓣膜的多中心经验。
J Heart Valve Dis. 2006 Jan;15(1):73-8; discussion 79.
9
Carpentier-Edwards porcine bioprostheses: clinical performance assessed by actual analysis.卡彭蒂埃-爱德华兹猪生物瓣膜:通过实际分析评估临床性能。
J Heart Valve Dis. 2000 Jul;9(4):530-5.
10
Evaluation of valve-related complications in patients with Sorin Bicarbon prosthesis: a seven-year experience.索林碳酸氢盐人工瓣膜患者瓣膜相关并发症的评估:七年经验
J Heart Valve Dis. 2001 Nov;10(6):795-801.

引用本文的文献

1
Gross age-related changes and diseases in human heart valves.人类心脏瓣膜与年龄相关的大体变化及疾病
Anat Cell Biol. 2019 Mar;52(1):25-33. doi: 10.5115/acb.2019.52.1.25. Epub 2019 Mar 29.
2
Trends in mechanical aortic valve replacement surgery in a large, multi-surgeon, single hospital practice.大型单医院多外科医生实施机械主动脉瓣置换手术的趋势
Kardiochir Torakochirurgia Pol. 2014 Dec;11(4):367-72. doi: 10.5114/kitp.2014.47334. Epub 2014 Nov 30.
3
Decision-making in aortic valve replacement: bileaflet mechanical valves versus stented bioprostheses.
主动脉瓣置换术的决策:双叶机械瓣膜与带支架生物瓣膜
Neth Heart J. 2003 Jan;11(1):5-10.
4
Single-centre experience of 101 paediatric and adult Ross procedures: mid-term results.101例儿童及成人Ross手术的单中心经验:中期结果
Interact Cardiovasc Thorac Surg. 2012 May;14(5):570-4. doi: 10.1093/icvts/ivr149. Epub 2012 Feb 22.
5
Two-dimensional FSI simulation of closing dynamics of a tilting disc mechanical heart valve.倾斜盘式机械心脏瓣膜关闭动力学的二维流固耦合模拟
J Med Device. 2010 Mar 1;4(1):11001. doi: 10.1115/1.4000876.
6
Two-dimensional simulation of flow and platelet dynamics in the hinge region of a mechanical heart valve.机械心脏瓣膜铰链区域血流与血小板动力学的二维模拟
J Biomech Eng. 2009 Mar;131(3):031002. doi: 10.1115/1.3005158.
7
Risk factors for pacemaker implantation following aortic valve replacement: a single centre experience.主动脉瓣置换术后起搏器植入的危险因素:单中心经验
Heart. 2003 Aug;89(8):901-4. doi: 10.1136/heart.89.8.901.